Our in vitro studies using primary cells and in vivo study using a mouse model of TGFα-induced pulmonary fibrosis demonstrates that nintedanib therapy is effective to attenuate fibroblast activation including fibroproliferation, resistance to apoptosis and ECM production in the mature fibrotic lung lesions. This evidence concerns the gene TGFA and pulmonary fibrosis.